

Table 2

Related Compound	F	Relative Retention Time vs. Moxifloxacin	Limit (%)
Specified unknown impurity #1	1.0	0.3	0.2
Decarboxy ¹	0.13	0.4	0.3
Specified unknown impurity #2	1.0	0.9	0.3
Any specified and identified impurity	1.0	—	1.0
Other single impurities	1.0	—	0.1
*Moxifloxacin related compound A	—	1.1	—
**8-Hydroxy ²	—	1.8	—

¹ 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-pyrrolo[3,4-b]pyridin-6-yl]-1H-quinolin-4-one.

² 1-Cyclopropyl-6-fluoro-8-hydroxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid.

* Disregard this peak because this is a process impurity controlled for the drug substance.

** Disregard this peak because it is quantitated using Test 2.

Table 3

Related Compound	F	Relative Retention Time vs. Moxifloxacin	Limit (%)
8-Hydroxy	0.29	1.8	0.2
Specified unknown impurity #3	1.0	3.4	0.2
Specified impurity #4*	0.42	3.9	0.2
Other single impurities	1.0	—	0.1
Total impurities (sum from both Test 1 and Test 2)	—	—	1.5

*7-Amino-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid.

Assay—

Buffer solution—Dissolve 0.5 g of tetrabutylammonium hydrogen sulfate and 1.0 g of monobasic potassium phosphate in 1000 mL of water, add 2 mL of phosphoric acid, filter, and degas.

Mobile phase—Use variable mixtures of Buffer solution and methanol as directed in Table 1. Make adjustments if necessary (see System Suitability under Chromatography (621)).

Resolution solution—Dissolve suitable quantities of USP Moxifloxacin Hydrochloride RS and USP Moxifloxacin Related Compound A RS in Buffer solution to obtain a solution containing about 0.1 mg per mg and 0.001 mg per mg, respectively.

Standard preparation—Dissolve an accurately weighed quantity of USP Moxifloxacin Hydrochloride RS in water to obtain a solution containing about 6 mg per mL. Dilute quantitatively, and stepwise if necessary, with the Buffer solution to obtain a solution having a known concentration of about 0.1 mg per mL.

Assay preparation—Transfer an accurately measured volume of Ophthalmic Solution, equivalent to about 5 mg of moxifloxacin, to a 50-mL volumetric flask, dilute with Buffer solution to volume, and mix.

Chromatographic system (see Chromatography (621))—The liquid chromatograph is equipped with a 293-nm detector and 4.0-mm × 25-cm column that contains 5-μm packing L11. The chromatograph is programmed as shown in Table 1. The column temperature is maintained at 45°. Chromatograph the Resolution solution, and record the peak responses as directed for Procedure: the resolution, R, between moxifloxacin and moxifloxacin related compound A is not less than 2.0. Chromatograph the Standard preparation, and record peak responses as directed for Procedure: the column efficiency is not less than 4000 theoretical plates; the tailing factor is not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%.


Procedure—Separately inject equal volumes (about 25 μL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the peak responses for the major peaks. Calculate the percent of

labeled amount of C₂₁H₂₄FN₃O₄ in the portion of the Ophthalmic Solution taken by the formula:

$$(401.43/437.89)(C_S/C_U)/(r_U/r_S)(100)$$

in which 401.43 and 437.89 are the molecular weights of moxifloxacin free base and moxifloxacin hydrochloride, respectively; C_S is the concentration, in mg per mL, of USP Moxifloxacin Hydrochloride RS in the Standard preparation; C_U is the concentration, in mg per mL, of Assay preparation based on the label claim; r_U and r_S are the peak responses obtained from the Assay preparation and Standard preparation, respectively; and 100 is the percent factor.

Mupirocin



C₂₆H₄₄O₉ 500.62

Nonanoic acid, 9-[[[3-methyl-1-oxo-4-[tetrahydro-3,4-dihydroxy-5-[[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-2H-pyran-2-yl]-2-butenyl]oxy]-[2S,2α(E),3β,4β,5α[2R*, 3R*(1R*,[2R*)]]]- (E)-(2S,3R,4R,5S)-5-[[[2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-β-methyl-2H-pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid [12650-69-0].

» Mupirocin contains not less than 920 μg and not more than 1020 μg of mupirocin (C₂₆H₄₄O₉) per mg, calculated on the anhydrous basis.

Packaging and storage—Preserve in tight containers.

USP Reference standards (11)—

USP Mupirocin RS

USP Mupirocin Lithium RS

Identification—The IR absorption spectrum of a mineral oil dispersion of it exhibits maxima only at the same wavelengths as that of a similar preparation of USP Mupirocin RS.

Crystallinity (695): meets the requirements.

pH (791): between 3.5 and 4.5, in a saturated aqueous solution.

Water, Method I (921): not more than 1.0%.

Assay—

pH 6.3 phosphate buffer—Prepare 0.05 M monobasic sodium phosphate, and adjust with 10 N sodium hydroxide to a pH of 6.3 ± 0.2 .

Mobile phase—Prepare a suitable mixture of *pH 6.3 phosphate buffer* and acetonitrile (750:250), pass through a suitable filter of 0.5 μm or finer porosity, and degas. Make adjustments if necessary (see *System Suitability* under *Chromatography* (621)).

Standard preparation—Transfer about 11 mg of USP Mupirocin Lithium RS, accurately weighed, to a 100-mL volumetric flask, add 25 mL of acetonitrile, and swirl to dissolve. Dilute with *pH 6.3 phosphate buffer* to volume, and mix.

Resolution solution—Adjust 10 mL of *Standard preparation* with 6 N hydrochloric acid to a pH of 2.0, allow to stand for 2 hours, and adjust with 5 N sodium hydroxide to a pH of 6.3 ± 0.2 .

Assay preparation—Transfer about 11 mg of Mupirocin, accurately weighed, to a 100-mL volumetric flask, add 25 mL of acetonitrile, and swirl to dissolve. Dilute with *pH 6.3 phosphate buffer* to volume, and mix.

Chromatographic system (see *Chromatography* (621))—The liquid chromatograph is equipped with a 229-nm detector and a 4.6-mm \times 25-cm column that contains packing L1 based on spherical silica particles. The flow rate is about 2 mL per minute. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*: the relative retention times are about 0.9 for the mupirocin acid hydrolysis product and 1.0 for mupirocin, and the resolution, R_s , between the mupirocin acid hydrolysis product and mupirocin is not less than 2.0. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the tailing factor is not more than 2, the column efficiency is not less than 1500 theoretical plates when calculated by the formula:

$$5.545(t_r / W_{h/2})^2$$


in which the terms are as defined therein. The relative standard deviation for replicate injections is not more than 2.0%.

Procedure—[NOTE—Use peak areas where peak responses are indicated.] Separately inject equal volumes (about 20 μL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in μg , of mupirocin ($\text{C}_{26}\text{H}_{44}\text{O}_9$) in each mg of Mupirocin taken by the formula:

$$(M_S E / M_U)(r_U / r_S)$$

in which M_S is the weight, in mg, of USP Mupirocin Lithium RS taken to prepare the *Standard preparation*; E is the mupirocin equivalent, in μg per mg, of USP Mupirocin Lithium RS; M_U is the weight, in mg, of mupirocin taken to prepare the *Assay preparation*; and r_U and r_S are the mupirocin peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.

Mupirocin Calcium



$\text{C}_{52}\text{H}_{86}\text{CaO}_{18} \cdot 2\text{H}_2\text{O}$ 1075.34

Nonanoic acid, 9-[[3-Methyl-1-oxo-4-[tetrahydro-3,4-dihydroxy-5-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-2H-pyran-2-yl]-2-butenyl]oxy-, calcium salt (2:1), dihydrate, [2S-[2 α (E),3 β ,4 β ,5 α][2R*,3R*(1R*,2R*)]]- (2S,3S,4R,5S)-5-[(2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy- β -methyl-2H-pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid, calcium salt (2:1), dihydrate [115074-43-6].

» Mupirocin Calcium contains the equivalent of not less than 865 μg and not more than 936 μg of mupirocin ($\text{C}_{26}\text{H}_{44}\text{O}_9$) per mg.

Packaging and storage—Preserve in tight containers. Store at 25°, excursions permitted between 15° and 30°.

USP Reference standards (11)—

USP Mupirocin Calcium RS

USP Mupirocin Lithium RS

Identification—

A: Infrared Absorption (197M)—[NOTE—Do not dry or grind extensively.]

B: The retention time of the major peak in the chromatogram of the *Assay preparation* corresponds to that in the chromatogram of the *Standard preparation*, as obtained in the *Assay*.

C: When moistened with hydrochloric acid, it meets the requirements of the flame test for *Calcium* (191).

Specific rotation (781S): between -16° and -20° .

Test solution: 50 mg per mL, in methanol.

Water, Method I (921): not less than 3.0% and not more than 4.5%.

Chloride (221)—Dissolve 50 mg in a mixture of 1 mL of 2 N nitric acid and 15 mL of methanol. Add 1 mL of silver nitrate TS: the turbidity does not exceed that produced by 0.70 mL of 0.020 N hydrochloric acid (0.5%).

Related compounds—

0.1 M Ammonium acetate—Prepare as directed in the *Assay*.

Mobile phase—Prepare a filtered and degassed mixture of 0.1 M *Ammonium acetate* and tetrahydrofuran (70:30). Make adjustments if necessary (see *System Suitability* under *Chromatography* (621)).

pH 4 Acetate buffer—Transfer about 13.6 g of sodium acetate to a 1000-mL volumetric flask, and dissolve in about 900 mL of water. Adjust with glacial acetic acid to a pH of 4.0, and dilute with water to volume.

Diluent—Prepare a mixture of *pH 4 Acetate buffer* and methanol (1:1).

Standard solution—Transfer about 25 mg of USP Mupirocin Lithium RS, accurately weighed, to a 200-mL volumetric flask, dissolve in and dilute with *Diluent* to volume, and mix.

Test solution—Transfer about 50 mg of Mupirocin Calcium, accurately weighed, to a 10-mL volumetric flask, dissolve in and dilute with *Diluent* to volume, and mix.

Resolution solution—Adjust 10 mL of the *Standard solution* with 6 N hydrochloric acid to a pH of 2.0, allow to stand for 20 hours, and adjust with 5 N sodium hydroxide to a pH of 4.0.

Chromatographic system (see *Chromatography* (621))—The liquid chromatograph is equipped with a 240-nm detector and a 4.6-mm \times 25-cm column that contains 5- μm packing L7. The flow rate is about 1 mL per minute. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*: two peaks are observed at retention times of about 0.63